#CEO David Dodd looks at the possible futures for GeoVax and the company’s focus during a surge in M&A activity.
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #GeneTherapy #HeadAndNeckCancer #SolidTumor #CancerResearch #Oncology #InnovativeMedicine #Biotech #TargetedTherapy

GeoVax' #CEO David A. Dodd looks at the Modified Vaccinia Ankara (MVA) platform & how $GOVX is adapting it to be used in developing and developed regions alike.
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #GeneTherapy #HeadAndNeckCancer #SolidTumor #CancerResearch #Oncology

GeoVax #CEO David Dodd emphasizes the importance of a multi-antigen vaccine. He calls for Congress to act in support of domestic biomanufacturing and biodevelopment.
$GOVX
#biotech #biotechnology #science #GeoVax #Gedeptin #GeneTherapy #CancerResearch #Oncology #InnovativeMedicine #Biotech

GeoVax CEO David Dodd compares the US and China's #biotech industries & shares steps to take to maintain our leading position.
$GOVX
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #GeneTherapy #HeadAndNeckCancer #SolidTumor #CancerResearch

GeoVax CEO David Dodd shares his management philosophy in the face of substantial change in the healthcare environment.
$GOVX
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #InnovativeMedicine #Biotech #TargetedTherapy #Immunotherapy #OrphanDrug #ClinicalTrials #CancerTreatment

Bavarian Nordic deal highlights M&A. Join CEO David Dodd who discusses the implications for @Geovax_News.
$GOVX
#biotech #biotechnology #science #Gedeptin #Biotech #ClinicalTrials #CancerTreatment

CEO David Dodd shares GeoVax' strategy for generating value driven by clinical development milestones.
$GOVX
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #Oncology #InnovativeMedicine #Biotech #TargetedTherapy #Immunotherapy #OrphanDrug #ClinicalTrials #CancerTreatment